Philippe Giral
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Philippe Giral has a total of 209 co-authors. Here are the top co-authors by number of shared publications:
- Bruna Gigante
Karolinska Institutet
7 shared publications - Dominique Bonnefont-Rousselot
APHP-Sorbonne Université, Pitié-Salpêtrière Hospital, Service de Biochimie Métabolique, Inserm UMR 1166 , Paris
7 shared publications - Damiano Baldassarre
Centro Cardiologico Monzino, IRCCS, 20138 Milan, Italy
6 shared publications - Elena Tremoli
GVM Care & Research, Maria Cecilia Hospital, 48033 Cotignola, Italy
6 shared publications - Eric Bruckert
Department of Endocrinology and Cardiovascular Disease Prevention, Assistance Publique-Hôpitaux de Paris, La Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France
6 shared publications - Fabrizio Veglia
Maria Cecilia Hospital, GVM Care & Research, 48033 Cotignola, Italy
6 shared publications
Latest Publications
- 22 October 2026
- Published by Oxford University Press (OUP) in Cardiovascular Research
miR-100-5p modulates postprandial triglyceride response by targeting PCSK9
Aims: Elevated postprandial hypertriglyceridaemia (PP-HTG) is a significant risk factor for the development of cardiovascular diseases; however, the mechanisms underlying its exaggerated rise remain poorly understood. MicroRNAs (miRs) are known to be implicated in the regulation of lipid metabolism, thus identifying them as potential key players. We presently investigated whether miRs may control postprandial triglyceride (PP-TG) response. Methods and results: Postprandial changes in circulating miR expression as a function of the degree of postprandial TG response were evaluated in non-dyslipidaemic healthy subjects (n = 32). The impact of miR-100-5p on hepatic gene expression was evaluated in differentiated Caco2 and HepG2 cells by analysis of hepatic transcriptome (RNAseq), western blot, and ELISA. In vivo studies were conducted in C57BL/6J mice overexpressing mimic miR-100-5p. Postprandial variation in circ-miR-100-5p levels inversely correlates with PP-TG response. Cir-miR-100-5p was preferentially associated with triglyceride-rich lipoprotein (TGRL) particles of intestinal origin in subjects who exhibited a low PP-TG response. Differential analysis of transcriptome from HepG2 cells transfected with either mimic miR-100-5p or scrambled mimic miR as control allowed to identify PCSK9 as a down-regulated gene. Overexpression of miR-100-5p in HepG2 cells significantly decreased PCSK9 mRNA levels by 52% (P < 0.0001), cellular protein content by 28% (P < 0.0001) as well as PCSK9 secretion by 39% (P < 0.0001). In vivo systemic delivery of mimic miR-100-5p induced a two-fold reduction (P < 0.0001) on PP-TG in mice, such effect being abolished by blocking the circulating form of PCSK9 with alirocumab. Finally, we revealed a significant inverse relationship between circulating miR-100-5p expression levels and both PCSK9 levels and the magnitude of postprandial hypertriglyceridaemia. Conclusion: Taken together, our observations reveal that miR-100-5p regulates postprandial hypertriglyceridaemia by targeting PCSK9, thus enhancing hepatic TGRL uptake. Our findings allow us to propose circ-miR-100-5p as a potential biomarker for early identification of subjects at high cardiovascular risk, before the appearance of classical clinical features of metabolic disorders. Postprandial clinical study: HDL-PP (NCT03109067).
- 22 October 2026
- Published by Oxford University Press (OUP) in Cardiovascular Research
miR-100-5p modulates postprandial triglyceride response by targeting PCSK9
Aims: Elevated postprandial hypertriglyceridaemia (PP-HTG) is a significant risk factor for the development of cardiovascular diseases; however, the mechanisms underlying its exaggerated rise remain poorly understood. MicroRNAs (miRs) are known to be implicated in the regulation of lipid metabolism, thus identifying them as potential key players. We presently investigated whether miRs may control postprandial triglyceride (PP-TG) response. Methods and results: Postprandial changes in circulating miR expression as a function of the degree of postprandial TG response were evaluated in non-dyslipidaemic healthy subjects (n = 32). The impact of miR-100-5p on hepatic gene expression was evaluated in differentiated Caco2 and HepG2 cells by analysis of hepatic transcriptome (RNAseq), western blot, and ELISA. In vivo studies were conducted in C57BL/6J mice overexpressing mimic miR-100-5p. Postprandial variation in circ-miR-100-5p levels inversely correlates with PP-TG response. Cir-miR-100-5p was preferentially associated with triglyceride-rich lipoprotein (TGRL) particles of intestinal origin in subjects who exhibited a low PP-TG response. Differential analysis of transcriptome from HepG2 cells transfected with either mimic miR-100-5p or scrambled mimic miR as control allowed to identify PCSK9 as a down-regulated gene. Overexpression of miR-100-5p in HepG2 cells significantly decreased PCSK9 mRNA levels by 52% (P < 0.0001), cellular protein content by 28% (P < 0.0001) as well as PCSK9 secretion by 39% (P < 0.0001). In vivo systemic delivery of mimic miR-100-5p induced a two-fold reduction (P < 0.0001) on PP-TG in mice, such effect being abolished by blocking the circulating form of PCSK9 with alirocumab. Finally, we revealed a significant inverse relationship between circulating miR-100-5p expression levels and both PCSK9 levels and the magnitude of postprandial hypertriglyceridaemia. Conclusion: Taken together, our observations reveal that miR-100-5p regulates postprandial hypertriglyceridaemia by targeting PCSK9, thus enhancing hepatic TGRL uptake. Our findings allow us to propose circ-miR-100-5p as a potential biomarker for early identification of subjects at high cardiovascular risk, before the appearance of classical clinical features of metabolic disorders. Postprandial clinical study: HDL-PP (NCT03109067).
- Open Access
- 26 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (3) , 584
Enhancing Cardiovascular Risk Prediction with a Simplified Carotid IMT Protocol: Evidence from the IMPROVE Study
Background/Objectives: Carotid intima-media thickness (CIMT) has long been used as an index of subclinical atherosclerosis, but its role as a risk modifier in cardiovascular (CV) risk optimization has recently been questioned due to methodological problems, such as lack of protocol standardization and scanning difficulties. In this multicentre, longitudinal, and observational study, we tested the predictive ability of two new CIMT variables detectable with a simplified, quick, and easy-to-standardize protocol. Methods: CIMT was measured in 3165 subjects from six centers, in five European countries, belonging to the IMPROVE study. The two variables tested were the average of two maximal CIMT measures taken, from a single angle, in the right and left common carotids (1CC-IMTmean-of-2-max) or bifurcations (BIF-IMTmean-of-2-max). The ability to predict CV events, on top of the SCORE2/SCORE2-OP risk algorithm, was quantified by the time-dependent increase in the receiver operating characteristic (ROC) area under the curve (AUC). Results: During a median follow-up of 7.1 years, 367 cardio-, cerebro-, and peripheral-vascular events were registered. Both CIMT variables tested were associated with CV risk, but 1CC-IMTmean-of-2-max was also able to significantly increase the ROC AUC over the risk score (+0.017, p = 0.014). The result was stable after running several sensitivity analyses. Conclusions: 1CC-IMTmean-of-2-max is able to significantly improve the predictive capacity of SCORE2/SCORE2-OP. Being based on a simple and easily standardized measurement protocol, this new variable is a promising candidate for application in mass screening and risk assessment in primary prevention.
- 26 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (3) , 584
Open AccessEnhancing Cardiovascular Risk Prediction with a Simplified Carotid IMT Protocol: Evidence from the IMPROVE Study
Background/Objectives: Carotid intima-media thickness (CIMT) has long been used as an index of subclinical atherosclerosis, but its role as a risk modifier in cardiovascular (CV) risk optimization has recently been questioned due to methodological problems, such as lack of protocol standardization and scanning difficulties. In this multicentre, longitudinal, and observational study, we tested the predictive ability of two new CIMT variables detectable with a simplified, quick, and easy-to-standardize protocol. Methods: CIMT was measured in 3165 subjects from six centers, in five European countries, belonging to the IMPROVE study. The two variables tested were the average of two maximal CIMT measures taken, from a single angle, in the right and left common carotids (1CC-IMTmean-of-2-max) or bifurcations (BIF-IMTmean-of-2-max). The ability to predict CV events, on top of the SCORE2/SCORE2-OP risk algorithm, was quantified by the time-dependent increase in the receiver operating characteristic (ROC) area under the curve (AUC). Results: During a median follow-up of 7.1 years, 367 cardio-, cerebro-, and peripheral-vascular events were registered. Both CIMT variables tested were associated with CV risk, but 1CC-IMTmean-of-2-max was also able to significantly increase the ROC AUC over the risk score (+0.017, p = 0.014). The result was stable after running several sensitivity analyses. Conclusions: 1CC-IMTmean-of-2-max is able to significantly improve the predictive capacity of SCORE2/SCORE2-OP. Being based on a simple and easily standardized measurement protocol, this new variable is a promising candidate for application in mass screening and risk assessment in primary prevention.
- Open Access
- 26 March 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (4) , 737
Determinants of Carotid Wall Echolucency in a Cohort of European High Cardiovascular Risk Subjects: A Cross-Sectional Analysis of IMPROVE Baseline Data
Echolucency, a measure of plaque instability associated with increased cardiovascular risk, can be assessed in both the carotid plaque and the plaque-free common carotid intima–media (IM) complex as a gray-scale median (plaque-GSM and IM-GSM, respectively). The impact of specific vascular risk factors on these two phenotypes remains uncertain, including the nature and extent of their influence. This study aims to seek the determinants of plaque-GSM and IM-GSM. Plaque-GSM and IM-GSM were measured in subjects from the IMPROVE study cohort (aged 54–79, 46% men) recruited in five European countries. Plaque-GSM was measured in subjects who had at least one IMTmax ≥ 1.5 mm (n = 2138), whereas IM-GSM was measured in all subjects included in the study (n = 3188). Multiple regression with internal cross-validation was used to find independent predictors of plaque-GSM and IM-GSM. Plaque-GSM determinants were plaque-size (IMTmax), and diastolic blood pressure. IM-GSM determinants were the thickness of plaque-free common carotid intima–media complex (PF CC-IMTmean), height, systolic blood pressure, waist/hip ratio, treatment with fibrates, mean corpuscular volume, treatment with alpha-2 inhibitors (sartans), educational level, and creatinine. Latitude, and pack-yearscode were determinants of both plaque-GSM and IM-GSM. The overall models explain 12.0% of plaque-GSM variability and 19.7% of IM-GSM variability. A significant correlation (r = 0.51) was found between plaque-GSM and IM-GSM. Our results indicate that IM-GSM is a weighty risk marker alternative to plaque-GSM, offering the advantage of being readily measurable in all subjects, including those in the early phases of atherosclerosis where plaque occurrence is relatively infrequent.
- 26 March 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (4) , 737
Open AccessDeterminants of Carotid Wall Echolucency in a Cohort of European High Cardiovascular Risk Subjects: A Cross-Sectional Analysis of IMPROVE Baseline Data
Echolucency, a measure of plaque instability associated with increased cardiovascular risk, can be assessed in both the carotid plaque and the plaque-free common carotid intima–media (IM) complex as a gray-scale median (plaque-GSM and IM-GSM, respectively). The impact of specific vascular risk factors on these two phenotypes remains uncertain, including the nature and extent of their influence. This study aims to seek the determinants of plaque-GSM and IM-GSM. Plaque-GSM and IM-GSM were measured in subjects from the IMPROVE study cohort (aged 54–79, 46% men) recruited in five European countries. Plaque-GSM was measured in subjects who had at least one IMTmax ≥ 1.5 mm (n = 2138), whereas IM-GSM was measured in all subjects included in the study (n = 3188). Multiple regression with internal cross-validation was used to find independent predictors of plaque-GSM and IM-GSM. Plaque-GSM determinants were plaque-size (IMTmax), and diastolic blood pressure. IM-GSM determinants were the thickness of plaque-free common carotid intima–media complex (PF CC-IMTmean), height, systolic blood pressure, waist/hip ratio, treatment with fibrates, mean corpuscular volume, treatment with alpha-2 inhibitors (sartans), educational level, and creatinine. Latitude, and pack-yearscode were determinants of both plaque-GSM and IM-GSM. The overall models explain 12.0% of plaque-GSM variability and 19.7% of IM-GSM variability. A significant correlation (r = 0.51) was found between plaque-GSM and IM-GSM. Our results indicate that IM-GSM is a weighty risk marker alternative to plaque-GSM, offering the advantage of being readily measurable in all subjects, including those in the early phases of atherosclerosis where plaque occurrence is relatively infrequent.
- 27 July 2023
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 17 (5) , 643-658
Integrated omics approach for the identification of HDL structure-function relationships in PCSK9-related familial hypercholesterolemia
- 27 July 2023
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 17 (5) , 643-658
Integrated omics approach for the identification of HDL structure-function relationships in PCSK9-related familial hypercholesterolemia
- Open Access
- 1 June 2023
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 16 (3) , 236-247
Cross-Sectional Gene-Smoking Interaction Analysis in Relation to Subclinical Atherosclerosis-Results From the IMPROVE Study
Background: Smoking is associated with carotid intima-media thickness (C-IMT). However, knowledge about how genetics may influence this association is limited. We aimed to perform nonhypothesis driven gene-smoking interaction analyses to identify potential genetic variants, among those included in immune and metabolic platforms, that may modify the effect of smoking on carotid intima-media thickness. Methods: We used baseline data from 1551 men and 1700 women, aged 55 to 79, included in a European multi-center study. Carotid intima-media thickness maximum, the maximum of values measured at different locations of the carotid tree, was dichotomized with cut point values ≥75, respectively. Genetic data were retrieved through use of the Illumina Cardio-Metabo- and Immuno- Chips. Gene-smoking interactions were evaluated through calculations of Synergy index (S). After adjustments for multiple testing, P values of −7 for S were considered significant. The models were adjusted for age, sex, education, physical activity, type of diet, and population stratification. Results: Our screening of 207 586 SNPs available for analysis, resulted in the identification of 47 significant gene-smoking synergistic interactions in relation to carotid intima-media thickness maximum. Among the significant SNPs, 28 were in protein coding genes, 2 in noncoding RNA and the remaining 17 in intergenic regions. Conclusions: Through nonhypothesis-driven analyses of gene-smoking interactions, several significant results were observed. These may stimulate further research on the role of specific genes in the process that determines the effect of smoking habits on the development of carotid atherosclerosis.
- 1 June 2023
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 16 (3) , 236-247
Open AccessCross-Sectional Gene-Smoking Interaction Analysis in Relation to Subclinical Atherosclerosis-Results From the IMPROVE Study
Background: Smoking is associated with carotid intima-media thickness (C-IMT). However, knowledge about how genetics may influence this association is limited. We aimed to perform nonhypothesis driven gene-smoking interaction analyses to identify potential genetic variants, among those included in immune and metabolic platforms, that may modify the effect of smoking on carotid intima-media thickness. Methods: We used baseline data from 1551 men and 1700 women, aged 55 to 79, included in a European multi-center study. Carotid intima-media thickness maximum, the maximum of values measured at different locations of the carotid tree, was dichotomized with cut point values ≥75, respectively. Genetic data were retrieved through use of the Illumina Cardio-Metabo- and Immuno- Chips. Gene-smoking interactions were evaluated through calculations of Synergy index (S). After adjustments for multiple testing, P values of −7 for S were considered significant. The models were adjusted for age, sex, education, physical activity, type of diet, and population stratification. Results: Our screening of 207 586 SNPs available for analysis, resulted in the identification of 47 significant gene-smoking synergistic interactions in relation to carotid intima-media thickness maximum. Among the significant SNPs, 28 were in protein coding genes, 2 in noncoding RNA and the remaining 17 in intergenic regions. Conclusions: Through nonhypothesis-driven analyses of gene-smoking interactions, several significant results were observed. These may stimulate further research on the role of specific genes in the process that determines the effect of smoking habits on the development of carotid atherosclerosis.
- 23 January 2023
- Published by Taylor & Francis in American Journal of Clinical Hypnosis
- Vol. 65 (4) , 281-298
Psychosocial effects of hypnosis in patients with obesity: a pilot randomized controlled trial
The usefulness of hypnosis in patients with obesity needs to be better understood in terms of various outcomes, in addition to weight loss. The aim of this research was to investigate the effects of hypnosis and self-hypnosis in combination with nutrition education for patients with obesity, as opposed to nutrition education alone, on the secondary outcomes of quality of life (QoL), coping strategies, and self-esteem within a randomized controlled trial (RCT). Eighty-two participants were included in this study (84.3% were women), with 41 in each group. Further, 70 participants had completed treatment. The intervention consisted of eight group sessions (about one every two weeks). Participants completed self-reported questionnaires assessing their QoL, coping strategies, and self-esteem (SF-36, CISS, SEI) before and after the intervention. Non-parametric analyses were performed. Both groups had comparable characteristics at inclusion (sociodemographic information, clinical information, and scores for the self-reported scales). At eight months (i.e. two months after intervention completion), patients from the hypnosis group used more task-oriented coping (p < .001), less emotion-oriented coping (p < .01) and distraction (p < .05), and had more energy/less fatigue (p < .001) compared to the group who did not undergo hypnosis. Other improvements were observed in the hypnosis group, but there were no significant differences compared with the non-hypnosis group in terms of QoL dimensions and general self-esteem. In conclusion, hypnosis and self-hypnosis in combination with nutrition education seem to be promising interventions to help patients deal with obesity, especially by improving their coping strategies.
- 23 January 2023
- Published by Taylor & Francis in American Journal of Clinical Hypnosis
- Vol. 65 (4) , 281-298
Psychosocial effects of hypnosis in patients with obesity: a pilot randomized controlled trial
The usefulness of hypnosis in patients with obesity needs to be better understood in terms of various outcomes, in addition to weight loss. The aim of this research was to investigate the effects of hypnosis and self-hypnosis in combination with nutrition education for patients with obesity, as opposed to nutrition education alone, on the secondary outcomes of quality of life (QoL), coping strategies, and self-esteem within a randomized controlled trial (RCT). Eighty-two participants were included in this study (84.3% were women), with 41 in each group. Further, 70 participants had completed treatment. The intervention consisted of eight group sessions (about one every two weeks). Participants completed self-reported questionnaires assessing their QoL, coping strategies, and self-esteem (SF-36, CISS, SEI) before and after the intervention. Non-parametric analyses were performed. Both groups had comparable characteristics at inclusion (sociodemographic information, clinical information, and scores for the self-reported scales). At eight months (i.e. two months after intervention completion), patients from the hypnosis group used more task-oriented coping (p < .001), less emotion-oriented coping (p < .01) and distraction (p < .05), and had more energy/less fatigue (p < .001) compared to the group who did not undergo hypnosis. Other improvements were observed in the hypnosis group, but there were no significant differences compared with the non-hypnosis group in terms of QoL dimensions and general self-esteem. In conclusion, hypnosis and self-hypnosis in combination with nutrition education seem to be promising interventions to help patients deal with obesity, especially by improving their coping strategies.
- Open Access
- 6 December 2022
- Published by Elsevier in Current Research in Translational Medicine
- Vol. 71 (1) , 103374
Causal analysis of plasma IL-8 on carotid intima media thickness, a measure of subclinical atherosclerosis
- 6 December 2022
- Published by Elsevier in Current Research in Translational Medicine
- Vol. 71 (1) , 103374
Open AccessCausal analysis of plasma IL-8 on carotid intima media thickness, a measure of subclinical atherosclerosis
- 2 November 2022
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 16 (6) , 765-768
Elevated LDL-cholesterol levels among lean mass hyper-responders on low-carbohydrate ketogenic diets deserve urgent clinical attention and further research
- 2 November 2022
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 16 (6) , 765-768
Elevated LDL-cholesterol levels among lean mass hyper-responders on low-carbohydrate ketogenic diets deserve urgent clinical attention and further research
- Open Access
- 20 August 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (38) , 3811
Targeted proteomics improves cardiovascular risk prediction in secondary prevention: the impact of statin treatment?
This commentary refers to ‘Targeted proteomics improves cardiovascular risk prediction in secondary prevention’, by N.S. Nurmohamed et al., https://doi.org/10.1093/eurheartj/ehac055 and the discussion piece 'Different inflammatory pathways underlying cardiovascular risk in secondary prevention', by N.S. Nurmohamed et al., https://doi.org/10.1093/eurheartj/ehac344.
- 20 August 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (38) , 3811
Open AccessTargeted proteomics improves cardiovascular risk prediction in secondary prevention: the impact of statin treatment?
This commentary refers to ‘Targeted proteomics improves cardiovascular risk prediction in secondary prevention’, by N.S. Nurmohamed et al., https://doi.org/10.1093/eurheartj/ehac055 and the discussion piece 'Different inflammatory pathways underlying cardiovascular risk in secondary prevention', by N.S. Nurmohamed et al., https://doi.org/10.1093/eurheartj/ehac344.
- Open Access
- 21 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (10) , 5792
APOE Molecular Spectrum in a French Cohort with Primary Dyslipidemia
Primary hypercholesterolemia is characterized by elevated LDL-cholesterol (LDL-C) levels isolated in autosomal dominant hypercholesterolemia (ADH) or associated with elevated triglyceride levels in familial combined hyperlipidemia (FCHL). Rare APOE variants are known in ADH and FCHL. We explored the APOE molecular spectrum in a French ADH/FCHL cohort of 5743 unrelated probands. The sequencing of LDLR, PCSK9, APOB, and APOE revealed 76 carriers of a rare APOE variant, with no mutation in LDLR, PCSK9, or APOB. Among the 31 APOE variants identified here, 15 are described in ADH, 10 in FCHL, and 6 in both probands. Five were previously reported with dyslipidemia and 26 are novel, including 12 missense, 5 synonymous, 2 intronic, and 7 variants in regulatory regions. Sixteen variants were predicted as pathogenic or likely pathogenic, and their carriers had significantly lower polygenic risk scores (wPRS) than carriers of predicted benign variants. We observed no correlation between LDL-C levels and wPRS, suggesting a major effect of APOE variants. Carriers of p.Leu167del were associated with a severe phenotype. The analysis of 11 probands suggests that carriers of an APOE variant respond better to statins than carriers of a LDLR mutation. Altogether, we show that the APOE variants account for a significant contribution to ADH and FCHL.
- 21 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (10) , 5792
Open AccessAPOE Molecular Spectrum in a French Cohort with Primary Dyslipidemia
Primary hypercholesterolemia is characterized by elevated LDL-cholesterol (LDL-C) levels isolated in autosomal dominant hypercholesterolemia (ADH) or associated with elevated triglyceride levels in familial combined hyperlipidemia (FCHL). Rare APOE variants are known in ADH and FCHL. We explored the APOE molecular spectrum in a French ADH/FCHL cohort of 5743 unrelated probands. The sequencing of LDLR, PCSK9, APOB, and APOE revealed 76 carriers of a rare APOE variant, with no mutation in LDLR, PCSK9, or APOB. Among the 31 APOE variants identified here, 15 are described in ADH, 10 in FCHL, and 6 in both probands. Five were previously reported with dyslipidemia and 26 are novel, including 12 missense, 5 synonymous, 2 intronic, and 7 variants in regulatory regions. Sixteen variants were predicted as pathogenic or likely pathogenic, and their carriers had significantly lower polygenic risk scores (wPRS) than carriers of predicted benign variants. We observed no correlation between LDL-C levels and wPRS, suggesting a major effect of APOE variants. Carriers of p.Leu167del were associated with a severe phenotype. The analysis of 11 probands suggests that carriers of an APOE variant respond better to statins than carriers of a LDLR mutation. Altogether, we show that the APOE variants account for a significant contribution to ADH and FCHL.